Kamada Ltd. Cements Position as Leader in Specialty Plasma-Derived Products with Impressive Q4 2025 Results
The company's fourth quarter and full-year 2025 financial results demonstrate its commitment to operational excellence, financial growth, and strategic planning.
According to the conference call transcript, Kamada Ltd. reported total revenues of $180.5 million for the year ended December 31, 2025, representing a 12% increase compared to the previous year. The company's adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) stood at $42 million, up 23% from the same period in 2024.
These results not only met but exceeded Kamada Ltd.'s 2025 annual guidance, showcasing its ability to execute on strategy and generate significant profitable growth through diversification of its commercial product portfolio. The company's focus on converting profitability into operational cash flow has also been successful, with $25.5 million generated from operating activities during the year.
Kamada Ltd.'s strong financial position enables it to pursue new business development and M&A transactions while paying dividends to shareholders. In this regard, the company declared a dividend of $0.25 per share, totaling approximately $14.4 million, payable on April 6 to shareholders of record as of March 23.
The declaration of this dividend payment reinforces Kamada Ltd.'s confidence in its business prospects and ability to maintain a strong liquidity position. This move is consistent with the company's dividend policy adopted by its board, under which it aims to distribute at least 50% of annual net income, subject to certain conditions.
Looking ahead to 2026, Kamada Ltd. affirms its revenue guidance at $200 million-$205 million and adjusted EBITDA guidance at $50 million-$53 million. These targets represent 13% and 23% growth compared to the midpoint of the previous year's results, respectively.
The company emphasizes that these projections are based solely on organic growth, indicating its commitment to sustainable expansion without relying on external factors. This stance aligns with Kamada Ltd.'s strategy to focus on the commercialization and lifecycle management of its six FDA-approved specialty plasma-derived products.
Kamada Ltd.'s positive outlook for 2026 underscores the company's confidence in its growth prospects, both in the near and longer term. Its strategies are centered around expanding its entire commercial product portfolio, driving organic commercial growth, and continuing to invest in its business development and M&A activities.
